Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Presentations
    • Overview
    • Press Releases
    • IR Calendar
    • Safe Harbor Statement
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Management Team
    • Contacts
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Presentations
  • Overview
  • Press Releases
  • IR Calendar
  • Safe Harbor Statement
  • Email Alerts

Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma

Feb 7, 2022

Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American

Feb 3, 2022

Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis

Dec 16, 2021

Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program

Dec 15, 2021

Navidea Biopharmaceuticals Terminates Stock Purchase Agreement

Dec 15, 2021

Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis

Dec 13, 2021

Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition

Dec 9, 2021

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Nov 10, 2021

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

Nov 3, 2021

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

Oct 26, 2021
RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...45
    © 2025 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap